CORTEXA
← Browse
openalexFrontiers in Oncology2026-07-23Cited by 0

Atypical imaging characteristics in patients with epithelial tumors of lacrimal gland and impact on initial surgical planning

Bita Esmaeli, Tracy Lu, Leena Ketonen, J. Matthew Debnam

Precis Approximately one-quarter of lacrimal gland masses present with imaging findings not consistent with standard teaching for benign vs. malignant; it is prudent to do gross total resection in such cases if eye-sparing surgery is possible. Background Epithelial lacrimal gland tumors are rare. The initial surgical decision to do an incisional biopsy vs. gross total resection depends largely on the radiologic characteristics of the lacrimal gland mass. Occasionally, the reported radiologic features attributed to benign vs. malignant lacrimal gland tumors do not hold. In this report, we will focus on these atypical presentations to help the orbital surgeon with better surgical planning. Methods Epithelial lacrimal gland tumors diagnosed in 101 consecutive patients (59 adenoid cystic carcinomas, 24 other carcinomas, and 18 pleomorphic adenomas) and treated by the primary author were included. The clinical and radiologic records were retrospectively reviewed. The clinical parameters analyzed included age, gender, histologic type, and surgical treatment. The radiologic data analyzed included radiologic characteristics of the lacrimal gland mass on the initial magnetic resonance imaging (MRI) and/or computed tomography (CT) at presentation. Cases that did not follow the “standard” imaging characteristics of carcinoma or pleomorphic adenoma were further analyzed. Results Overall, two possible atypical radiologic patterns were identified: (1) 11 of 59 (19%) cases of adenoid cystic carcinoma and 5 of 24 (21%) cases of other carcinomas were identified where the lesion was round and well-circumscribed, lacked a posterior extension or other aggressive features, and could not be distinguished from pleomorphic adenoma but after surgical resection were found to be adenoid cystic carcinoma or other types of lacrimal gland carcinoma; (2) 5 of 18 (28%) cases of pleomorphic adenoma presented with large multilobular masses and could not be distinguished from a carcinoma but in fact were found to be of benign nature on histologic evaluation. Conclusions Our findings suggest some overlap in radiologic features between pleomorphic adenomas and lacrimal gland carcinomas. Given the risk of multifocal benign or malignant recurrence of pleomorphic adenomas if excised incompletely, it seems prudent to err on the side of gross total resection for most well-circumscribed lesions of the lacrimal gland that lack aggressive radiologic features. Some of these well-circumscribed lesions will end up being adenoid cystic carcinoma or other types of lacrimal gland carcinomas upon pathologic evaluation of the surgical specimen and may require additional treatments.

View free PDFSource page

Related papers

openalexFrontiers in Oncology2026-07-24

Adenomatoid tumor of the testis in a patient with history of cryptorchidism, male breast cancer, and thymic B2 thymoma: a case report and literature review

Yunpeng Cao, Xi Zhang, Feifan Song, Lu Liu, Xiongjie Cui, Shen Li, et al.

Background Adenomatoid tumor is a rare benign neoplasm of mesothelial origin, most commonly arising in the epididymis, vas deferens, and tunica vaginalis; primary occurrence in the testis is extremely rare. Cryptorchidism is recognized as a risk factor for testicular germ cell tu…

View free PDFSource page
openalexFrontiers in Oncology2026-07-24

Editorial: Innovative diagnostic and therapeutic strategies for neuroendocrine tumors: a multidisciplinary approach

Patricia Borges de Souza, Matteo Zurlo, Sara BRAVACCINI, Martina Rosticci, Massimiliano Mazza, Maria Chiara Zatelli

In this context, this Research Topic was conceived to highlight innovative diagnostic and therapeutic strategies to advance precision medicine in NENs. Although the contributions address diverse clinical and translational questions, they converge on a common theme: improving pati…

View free PDFSource page
openalexFrontiers in Oncology2026-07-24

Symptom cluster profiles and their impact on quality of life in Chinese patients with prostate cancer undergoing ADT: a cross-sectional study

Yingchao Xiao, Huichao Chen, Zhiqiang Chen, Juan Chen, Zi Wang, Aihua Ou, et al.

Background Despite the growing burden of prostate cancer in China and the widespread use of androgen deprivation therapy (ADT), no validated disease-specific instrument has been used to systematically characterize symptom clusters and their impact on quality of life (QoL) in this…

View free PDFSource page
openalexFrontiers in Oncology2026-07-23

A case report of uterine adenosarcoma with sarcomatous overgrowth and pulmonary metastasis

Xiaotian Qi, Q Q Wang, Jiutao Zheng, Nana Guo, Zhichun Zhang, Hongli Li, et al.

Background Uterine adenosarcoma is a rare malignant tumor characterized by a biphasic pattern consisting of benign epithelial components and sarcomatous stroma. The subtype with sarcomatous overgrowth is more aggressive and poses significant challenges in clinical diagnosis and m…

View free PDFSource page
openalexFrontiers in Oncology2026-07-23

Editorial: Liquid biopsy in non-small cell lung cancer for diagnosis, treatment selection and monitoring

A. Strati, Benoît Roch, Ammar Sukari

Lung cancer is the third most common malignancy in the United States and remains the leading cause of cancer-related mortality worldwide. Despite ongoing advances in diagnosis and therapy, survival rates for patients with lung cancer remain unsatisfactory (1). In recent years, in…

View free PDFSource page
openalexFrontiers in Oncology2026-07-23

Real-world treatment patterns and outcomes of chemo-immunotherapy with or without radiotherapy in extensive-stage small cell lung cancer: the durvalumab expanded access cohort

Urška Janžič, Walid Shalata, Mojca Unk, Ana Sophie Terglav, Natali Shirron, Sameh Daher, et al.

Purpose To describe real-world treatment patterns and outcomes among patients with extensive-stage small cell lung cancer (ES-SCLC) treated with first-line chemotherapy plus durvalumab as in CASPIAN trial within Expanded Access Program, with a focus on the use and impact of conso…

View free PDFSource page